Bristol-Myers Squibb Company

US$62.14As of Sun 8 Nov 2026, 12:00 UTC

NYSE:BMYHealthcare

Country USA

PE (Fwd) •••

TSR 10Y CAGR 5.70%

Div yield 4.05%

ROE 44.01%

Drug Manufacturers (General)

Beta (5Y) 0.19

PE TTM 13.77

TSR TTM 40.88%

Mkt cap US$127.0B

ROIC 23.60%

SE Grade™

—

Value

Quality

Moat

Consensus

Reference

$64

2.84%

463.53%

Hold 11|7|1|8|1

TTM

FYE 31 Dec USD

FY2016

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026E

Trend

10Y

Peers

10.38

Revenue$B

13.96

14.74

15.51

16.66

17.77

19.13

20.20

21.29

23.16

25.24

11.27

7.27%

6.98%

11.81

Revenue growth%

6.74

6.52

4.89

3.68

4.17

2.92

2.61

2.13

4.97

7.87

29.00

2.92

4.53

26.32

Gross margin%

15.18

12.50

12.79

12.33

10.96

12.56

12.43

13.98

13.54

15.07

4.00

13.54

12.67

22.94

Operating margin%

8.83

6.57

9.12

8.89

8.76

9.58

7.59

9.18

11.39

14.21

11.97

9.58

9.01

26.43

Net margin%

4.79

6.75

9.73

6.84

5.14

5.83

3.94

0.98

1.05

3.29

9.93

3.29

4.96

31.66

P/E ratio (avg)x

25.19

24.41

27.80

31.92

36.41

36.98

36.41

41.82

47.81

52.45

15.28

41.82

36.41

33.37

EV/EBITx

20.56

22.76

25.52

24.64

25.90

24.03

25.11

27.96

31.60

33.38

13.07

27.96

25.32

23.05

FCF yield (avg)%

9.52

10.80

13.36

15.17

15.08

12.68

11.02

9.97

8.44

9.27

17.16

9.97

10.91

14.02

FCF margin%

19.65

19.61

21.58

22.59

22.91

21.47

21.11

18.43

18.74

18.51

2.27

18.74

20.38

0.912

FCF / Net incomex

1.628

1.469

1.587

1.407

1.284

1.146

1.199

1.066

1.037

0.957

1.040

1.066

1.241

4.88

ROIC%

2.82

1.80

2.01

0.40

2.75

0.40

0.92

28.81

0.40

0.66

6.22

Return on equity%

27.61

26.43

27.67

28.34

26.55

27.58

28.78

26.71

23.93

22.60

22.48

26.71

27.14

9.97

Return on assets%

9.94

10.01

9.14

7.93

8.09

8.18

5.89

8.56

9.22

9.70

15.87

8.56

8.85

10.22

EPS$

11.38

11.22

13.40

14.39

14.52

15.66

15.08

14.72

15.48

17.14

10.91

3.38%

3.83%

—

10.11

EPS growth%

7.30

9.33

7.77

6.11

7.29

6.22

7.96

5.54

4.11

1.11

17.00

5.54

6.76

8.75

Bookvalue per sh$

4.69

5.05

5.48

5.26

5.47

5.83

5.48

5.45

5.55

5.10

10.03

(1.39%)

1.05%

—

7.54

FCF per share$

14.25

16.76

17.31

17.67

17.71

20.73

20.86

19.91

19.62

20.52

1.55

3.00%

3.80%

—

2.93

Dividend per sh$

11.54

13.00

12.50

13.84

14.81

17.65

17.84

20.32

20.52

22.57

7.46

8.79%

6.85%

—

25.40

Div yield (avg)%

16.94

19.39

21.30

22.30

21.24

18.47

17.96

18.42

17.98

18.61

16.03

18.42

18.54

25.66

Payout ratio%

13.52

13.72

15.50

13.11

10.28

8.00

5.57

5.31

4.14

4.67

27.65

5.31

9.14

2.020

Shares (diluted)B

2.027

1.981

1.962

1.875

1.786

1.880

2.033

2.250

2.294

2.247

2.021

4.70%

0.77%

17.36

Buyback yield%

12.71

12.77

12.83

10.52

10.35

12.31

13.81

14.12

12.01

11.51

26.03

12.31

12.51

0.376

D/E ratiox

1.940

2.141

2.523

2.594

2.857

3.237

3.628

3.681

4.412

4.742

1.656

3.681

3.047

19.90

Enterprise value$B

13.02

12.13

11.52

12.18

13.00

12.05

11.84

11.31

12.92

13.43

27.46

0.64%

0.48%

2.825

LT debt$B

10.90

11.68

11.71

11.25

10.87

10.06

11.18

10.36

11.65

12.48

26.68

2.80%

1.82%

Peers (US$127.0B)

Cap (US$)

Amgen Inc.

249.0B

26.68x

Gilead Sciences, Inc.

207.0B

—

Pfizer Inc.

167.5B

41.88x

Sanofi

112.7B

24.22x

Capital

TTM

10Y

Leveragex

6.098

(0.256)

(0.207)

EBIT/Intx

0.935

0.105

0.086

Own earn%

(176.13)

(181.96)

(188.94)

Sh yield%

42.76

30.78

31.68

Owners

Insiders/Inst%

11.49

89.97

Short interest%

5.13

SBC / revenue%

1.86

Record

10Y

Profitable years

10/10

Revenue growth years

10/10

EPS growth years

10/10

Dividend streakyrs

Op margin range%

7–14

$1 testx

—

Incr. ROIC%

Bristol-Myers Squibb Company discovers, develops, manufactures, markets and sells biopharmaceutical products worldwide for oncology, hematology, immunology, cardiovascular and neuroscience indications, including Opdivo, Eliquis, Revlimid, Yervoy, Orencia, Breyanzi, Camzyos, Zeposia, Reblozyl and Cobenfy. It sells to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics and government agencies.

Growth vs revenue

Latest

Trend

10Y CAGR

Rel growth

Revenue

$25.24B

6.98%

1.00×

Cost of revenue

$13.67B

7.22%

1.02×

Operating expenses

$5.972B

6.74%

0.98×